

# Learner Notification

---

## Kneed Communications

### Los Angeles - Advancing the Diagnostic-to-Treatment Continuum in Cancer Care

February 27, 2026 - February 28, 2026

Los Angeles, CA

#### **Acknowledgement of Financial Commercial Support**

No financial commercial support was received for this educational activity.

#### **Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

#### **Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

#### **Joint Accreditation Statement**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Kneed Communications. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

#### **Physicians**

Amedco LLC designates this live activity for a maximum of 8.00 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **Pharmacists & Pharmacy Technicians**

Amedco LLC designates this activity for a maximum of 8.00 knowledge-based CPE contact hours.

UAN JA4008163-9999-26-069-L01-P

**NOTE to Pharmacists:** *The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.*

#### **Nurses**

Amedco LLC designates this activity for a maximum of 8.00 ANCC contact hours.

#### **American Board of Pathology (ABPath) MOC**

This activity is registered with the American Board of Pathology Maintenance of Certification Program for Self-Assessment Module (SAM) for 8.00 credit hours.

**You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.**

## Objectives - After Attending This Program You Should Be Able To

1. Integrate evidence-based advances from both pathology and oncology to enhance biomarker testing, diagnosis, and treatment planning for solid tumors and hematologic malignancies.
2. Apply multidisciplinary insights and new clinical data to improve therapeutic decision-making and patient outcomes across diverse practice settings.

## Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Leonidas Arvanitis	NA
Marwan Fakih	AbbVie, Adagene, BMS, Delcath, Iterion, Merck, Microbial Machines, Revolution Medicines, Summit Therapeutics, Taiho, Totus Medicines:Consultant Exelixis, Janssen, Merus N.V., Roche/Genentech, Tempus, Xilio Therapeutics, :Scientific/Medical Advisory Board Member
Fang Fan	AstraZeneca:Scientific/Medical Advisory Board Member
Eric Glassy	Gestalt, Leica BioSystems:Scientific/Medical Advisory Board Member Evident, Merck, Ventana, AstraZeneca:Consultant
Stephen Gruber	Abbvie, Eisai, Halo Dx, Johnson & Johnson, Astra Zeneca:Research Grant Site Principal Investigator Genvivo:Scientific/Medical Advisory Board Member
Stanley Hamilton	NA
Joanne Jeter	NA
Christine Lovly	AbbVie, Amgen, AnHeart, Astra Zeneca, Bayer, Black Diamond, BMS, Boehringer Ingelheim, Cepheid, D2G, Daiichi Sankyo, Danaher, Exact, Foresight, Foundation Medicine, Guardant, Genentech, Gilead, Immuni:Consultant
Guido Marcucci	Ostentus :Private Stock Shareholder Sokey:Scientific/Medical Advisory Board Member
Kevin McDonnell	NA
Hope Rugo	for Napo, Bristol Myers Squibb, Helsinn, and BioNTech:Consultant AstraZeneca, Gilead Sciences, Inc., Lilly, Merck & Co., Daiichi Sankyo, Inc., Novartis Pharmaceuticals, Pfizer, F. Hoffman-La Roche/Genentech, Stemline Therapeutics, Ambryx with prior institution, Bicycle Therapeutics, F. Hoffman-La Roche/Genentech, Merck & Co., and Stemline Therapeutics with current institution:Research Grant Site Principal Investigator
Deanna Russell	NA
Nigel Russell	NA
Ravi Salgia	NA
N. Jewel Samadder	Recursion Pharmaceuticals, Parabilis Pharmaceuticals:Consultant
Ilana Solomon	NA
M. James You	NA
Naomi Terlouw	NA

## How to Get Your Certificate

1. Go to [kc.cmecertificateonline.com](https://kc.cmecertificateonline.com)
  2. Click on the **2026 Los Angeles - Advancing the Diagnostic-to-Treatment Continuum in Cancer Care** link.
  3. Evaluate the meeting.
  4. Print, download, or save your certificate for your records.
  5. If you lose your certificate, or need help, go to [help.cmecertificateonline.com](https://help.cmecertificateonline.com)
-